论文部分内容阅读
目的:探讨减低剂量去甲柔红霉素联合阿糖胞苷(IA)方案治疗老年急性髓细胞白血病(AML)患者的疗效。方法:收集我院老年急性髓细胞白血病患者62例,随机分成减低剂量IA治疗组和标准剂量IA对照组,两组均实施3+7治疗方案。治疗2个疗程,比较两组不良反应和临床疗效。结果:减低剂量IA治疗组总CR率和CCR率分别为75.0%和66.7%;标准剂量IA对照组总CR率和CCR率分别为50.0%和33.3%。减低剂量IA治疗组总生存期25+月较标准剂量IA对照组生存期23+月延长。结论:对于老年急性髓细胞白血病患者,减低剂量IA治疗方案的CR率和CCR率与标准剂量IA治疗方案相比具有明显疗效优势。
Objective: To investigate the effect of reducing the dose of daunorubicin combined with cytarabine (IA) in the treatment of elderly patients with acute myeloid leukemia (AML). Methods: Sixty-two elderly patients with acute myeloid leukemia were collected and randomly divided into two groups: IA reduced dose group and IA standard dose group. Both groups received 3 + 7 treatment. Treatment of 2 courses, compared two groups of adverse reactions and clinical efficacy. Results: The total CR rate and CCR rate were 75.0% and 66.7% respectively in the IA-treated group and 50.0% and 33.3% in the standard-dose IA control group. Reduced dose IA treatment group total survival 25 + month than the standard dose IA control group 23 + month survival. CONCLUSIONS: CR rates and CCR rates for reduced-dose IA regimens are significantly superior to standard-dose IA regimens for elderly patients with acute myeloid leukemia.